References

1. 1..
   Nors J,Iversen LH,Erichsen R,Gotschalck KA,Andersen CL. Incidence of recurrence and time to recurrence in stage I to III colorectal cancer: a nationwide danish cohort study. JAMA Oncol. 2024;10(1):54-62.
2. 2..
   Fu H. Novel molecular mechanisms and clinical strategies in solid tumor recurrence and metastasis: from bench to bedside. Front Med(Lausanne). 2024;11:1364666.
3. 3..
   Chakraborty G,Gupta K,Kyprianou N. Epigenetic mechanisms underlying subtype heterogeneity and tumor recurrence in prostate cancer. Nat Commun. 2023;14(1):567.
4. 4..
   Liu R,Zhao Y,Su S,Kwabil A,Njoku PC,Yu H, et al. Unveiling cancer dormancy: intrinsic mechanisms and extrinsic forces. Cancer Lett.2024;591:216899.
5. 5..
   Aouad P,Quinn HM,Berger A,Brisken C. Tumor dormancy: EMT beyond invasion and metastasis. Genesis. 2024;62(1):e23552.
6. 6..
   Rosano D,Sofyali E,Dhiman H,Ghirardi C,Ivanoiu D,Heide T, et al. Long-term multimodal recording reveals epigenetic adaptation routes in dormant breast cancer cells. Cancer Discov. 2024;14(5):866-89.
7. 7..
   Llinas-Bertran A,Bellet-Ezquerra M,Seoane JA. Epigenetic control of cancer cell dormancy and awakening in endocrine therapy resistance. Cancer Discov. 2024;14(5):704-6.
8. 8..
   Cheng SH,Chiou HC,Wang JW,Lin MH. Reciprocal regulation of cancer-associated fibroblasts and tumor microenvironment in gastrointestinal cancer: implications for cancer dormancy. Cancers. 2023;15(9):2513.
9. 9..
   Min HY,Lee HY. Cellular dormancy in cancer: mechanisms and potential targeting strategies. Cancer Res Treat. 2023;55(3):720-36.
10. 10..
    Santos-de-Frutos K,Djouder N. When dormancy fuels tumour relapse. Commun Biol. 2021;4(1):747.
11. 11..
    Manjili MH. Tumor dormancy and relapse: from a natural byproduct of evolution to a disease state. Cancer Res. 2017;77(10):2564-9.
12. 12..
    Truskowski K,Amend SR,Pienta KJ. Dormant cancer cells: Pro-grammed quiescence, senescence, or both? Cancer Metastasis Rev.2023;42(1):37-47.
13. 13..
    Weston WA,Barr AR. A cell cycle centric view of tumour dormancy. Br J Cancer. 2023;129(10):1535-45.
14. 14..
    Endo H,Inoue M. Dormancy in cancer. Cancer Sci. 2019;110(2):474-80.
15. 15..
    Kumari R,Jat P. Mechanisms of cellular senescence: cell cycle arrest and senescence associated secretory phenotype. Front Cell Dev Biol.2021;9:645593.
16. 16..
    Easwaran S,Montell DJ. The molecular mechanisms of diapause and diapause-like reversible arrest. Biochem Soc Trans. 2023;51(5):1847-56.
17. 17..
    Hussein AM,Balachandar N,Mathieu J,Ruohola-Baker H. Molecular regulators of embryonic diapause and cancer diapause-like state. Cells.2022;11(19):2929.
18. 18..
    Butturini E,de Prati AC,Boriero D,Mariotto S. Tumor dormancy and interplay with hypoxic tumor microenvironment. Int J Mol Sci.2019;20(17):4305.
19. 19..
    Park SY,Nam JS. The force awakens: metastatic dormant cancer cells. Exp Mol Med. 2020;52(4):569-81.
20. 20..
    Ganesan R,Bhasin SS,Bakhtiary M,Krishnan U,Cheemarla NR,Thomas BE, et al. Taxane chemotherapy induces stromal injury that leads to breast cancer dormancy escape. PLoS Biol. 2023;21(9):e3002275.
21. 21..
    Damen MPF,van Rheenen J,Scheele CLGJ. Targeting dormant tumor cells to prevent cancer recurrence. FEBS J. 2021;288(21):6286-303.
22. 22..
    Perego M,Tyurin VA,Tyurina YY,Yellets J,Nacarelli T,Lin C, et al. Reactivation of dormant tumor cells by modified lipids derived from stress-activated neutrophils. Sci Transl Med. 2020;12(572):eabb5817.
23. 23..
    Pranzini E,Raugei G,Taddei ML. Metabolic features of tumor dormancy:possible therapeutic strategies. Cancers (Basel). 2022;14(3):547.
24. 24..
    Miller AK,Brown JS,Enderling H,Basanta D,Whelan CJ. The evolution-ary ecology of dormancy in nature and in cancer. Front Ecol Evol.2021;9:676802.
25. 25..
    Vera-Ramirez L,Vodnala SK,Nini R,Hunter KW,Green JE. Autophagy promotes the survival of dormant breast cancer cells and metastatic tumour recurrence. Nat Commun. 2018;9(1):1944.
26. 26..
    Singvogel K,Schittek B. Dormancy of cutaneous melanoma. Cancer Cell Int. 2024;24(1):88.
27. 27..
    Liu ZL,Chen HH,Zheng LL,Sun LP,Shi L. Angiogenic signaling path-ways and anti-angiogenic therapy for cancer. Signal Transduct Target Ther. 2023;8(1):198.
28. 28..
    Jiang X,Wang J,Deng X,Xiong F,Zhang S,Gong Z, et al. The role of microenvironment in tumor angiogenesis. J Exp Clin Cancer Res.2020;39(1):204.
29. 29..
    Naumov GN,Bender E,Zurakowski D,Kang SY,Sampson D,Flynn E, et al. A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst. 2006;98(5):316-25.
30. 30..
    Folkman J,Watson K,Ingber D,Hanahan D. Induction of angiogen-esis during the transition from hyperplasia to neoplasia. Nature.1989;339(6219):58-61.
31. 31..
    Huang Z,Bao SD. Roles of main pro- and anti-angiogenic factors in tumor angiogenesis. World J Gastroenterol. 2004;10(4):463-70.
32. 32..
    Satchi-Fainaro R,Ferber S,Segal E,Ma L,Dixit N,Ijaz A, et al. Prospective identification of glioblastoma cells generating dormant tumors. PLoS One. 2012;7(9):e44395.
33. 33..
    Wang SH,Lin SY. Tumor dormancy: potential therapeutic target in tumor recurrence and metastasis prevention. Exp Hematol Oncol.2013;2(1):29.
34. 34..
    Patel SA,Ramkissoon SH,Bryan M,Pliner LF,Dontu G,Patel PS, et al. Delineation of breast cancer cell hierarchy identifies the subset respon-sible for dormancy. Sci Rep. 2012;2:906.
35. 35..
    Lin S,Chai Y,Zheng X,Xu X. The role of HIF in angiogenesis, lymphangi-ogenesis, and tumor microenvironment in urological cancers. Mol Biol Rep. 2023;51(1):14.
36. 36..
    Wu Q,You L,Nepovimova E,Heger Z,Wu W,Kuca K, et al. Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape. J Hematol Oncol. 2022;15(1):77.
37. 37..
    Huang T,Sun L,Yuan X,Qiu H. Thrombospondin-1 is a multifaceted player in tumor progression. Oncotarget. 2017;8(48):84546-58.
38. 38..
    Lawler J. Thrombospondin-1 as an endogenous inhibitor of angiogen-esis and tumor growth. J Cell Mol Med. 2002;6(1):1-12.
39. 39..
    Wang Z,Li J,Guo J,Wei P. Direct antitumor activity of bevacizumab: an overlooked mechanism? Front Pharmacol. 2024;15:1394878.
40. 40..
    Vasudev NS,Reynolds AR. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis.2014;17(3):471-94.
41. 41..
    Qi S,Deng S,Lian Z,Yu K. Novel drugs with high efficacy against tumor angiogenesis. Int J Mol Sci. 2022;23(13):6934.
42. 42..
    Okabe Y,Medzhitov R. How the immune system spots tumors. eLife.2014;3:e04476.
43. 43..
    Kim SK,Cho SW. The evasion mechanisms of cancer immunity and drug intervention in the tumor microenvironment. Front Pharmacol.2022;13:868695.
44. 44..
    Baxevanis CN,Perez SA. Cancer dormancy: a regulatory role for endog-enous immunity in establishing and maintaining the tumor dormant state. Vaccines (Basel). 2015;3(3):597-619.
45. 45..
    Wang HF,Wang SS,Huang MC,Liang XH,Tang YJ,Tang YL. Targeting immune-mediated dormancy: a promising treatment of cancer. Front Oncol. 2019;9:498.
46. 46..
    Taylor BC,Balko JM. Mechanisms of MHC-I downregulation and role in immunotherapy response. Front Immunol. 2022;13:844866.
47. 47..
    Chang Y,Chen J. Dormant mechanisms reveal the clinical significance of tumor dormancy: a narrative review. Ann Blood. 2021. .
48. 48..
    Rafiq S,Hackett CS,Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol.2020;17(3):147-67.
49. 49..
    Uscanga-Palomeque AC,Chávez-Escamilla AK,Alvizo-Báez CA,Saavedra-Alonso S,Terrazas-Armendáriz LD,Tamez-Guerra RS, et al. CAR-T cell therapy: from the shop to cancer therapy. Int J Mol Sci.2023;24(21):15688.
50. 50..
    Huang Z,Dewanjee S,Chakraborty P,Jha NK,Dey A,Gangopadhyay M, et al. CAR T cells: engineered immune cells to treat brain cancers and beyond. Mol Cancer. 2023;22(1):22.
51. 51..
    Shah NN,Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019;16(6):372-85.
52. 52..
    Wang JY,Wang L. CAR-T cell therapy: where are we now, and where are we heading? Blood Sci. 2023;5(4):237-48.
53. 53..
    Foeng J,Comerford I,McColl SR. Harnessing the chemokine system to home CAR-T cells into solid tumors. Cell Rep Med. 2022;3(3):100543.
54. 54..
    Scarfò I,Maus MV. Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment. J Immunother Cancer. 2017;5(1):28.
55. 55..
    Wilczyński JR,Nowak M. Cancer immunoediting: elimination, equilib-rium, and immune escape in solid tumors. Exp Suppl. 2022;113:1-57.
56. 56..
    Mittal D,Gubin MM,Schreiber RD,Smyth MJ. New insights into cancer immunoediting and its three component phases-elimination, equilib-rium and escape. Curr Opin Immunol. 2014;27:16-25.
57. 57..
    Bates JP,Derakhshandeh R,Jones L,Webb TJ. Mechanisms of immune evasion in breast cancer. BMC Cancer. 2018;18(1):556.
58. 58..
    Chernosky NM,Tamagno I. The role of the innate immune system in cancer dormancy and relapse. Cancers (Basel). 2021;13(22):5621.
59. 59..
    Rotte A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J Exp Clin Cancer Res. 2019;38(1):255.
60. 60..
    Buchbinder EI,Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol.2016;39(1):98-106.
61. 61..
    Mehdizadeh R,Shariatpanahi SP,Goliaei B,Peyvandi S,Rüegg C. Dormant tumor cell vaccination: a mathematical model of immu-nological dormancy in triple-negative breast cancer. Cancers (Basel).2021;13(2):245.
62. 62..
    Dailey GP,Crosby EJ,Hartman ZC. Cancer vaccine strategies using self-replicating RNA viral platforms. Cancer Gene Ther. 2023;30(6):794-802.
63. 63..
    Ferrer AI,Trinidad JR,Sandiford O,Etchegaray JP,Rameshwar P. Epige-netic dynamics in cancer stem cell dormancy. Cancer Metastasis Rev.2020;39(3):721-38.
64. 64..
    Robinson NJ,Parker KA,Schiemann WP. Epigenetic plasticity in meta-static dormancy: mechanisms and therapeutic implications. Ann Transl Med. 2020;8(14):903.
65. 65..
    Jain D,Herzog BH,Maggi LB. Genetic alterations in cancer. In: Govindan R, Devarakonda S, editors. Cancer genomics for the clinician. New York:Springer; 2019. p. 1–14.
66. 66..
    Herceg Z,Hainaut P. Genetic and epigenetic alterations as bio-markers for cancer detection, diagnosis and prognosis. Mol Oncol.2007;1(1):26-41.
67. 67..
    Harada K,Baba Y,Shigaki H,Ishimoto T,Miyake K,Kosumi K, et al. Prognostic and clinical impact of PIK3CA mutation in gastric cancer:pyrosequencing technology and literature review. BMC Cancer.2016;16(1):400.
68. 68..
    Huang L,Guo Z,Wang F,Fu L. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct Target Ther. 2021;6(1):386.
69. 69..
    Barras D. BRAF mutation in colorectal cancer: an update. Biomark Cancer. 2015;7(Suppl 1):9-12.
70. 70..
    Luk PP,Yu B,Ng CC,Mercorella B,Selinger C,Lum T, et al. BRAF mutations in non-small cell lung cancer. Transl Lung Cancer Res.2015;4(2):142-8.
71. 71..
    Negrao MV,Raymond VM,Lanman RB,Robichaux JP,He J,Nilsson MB, et al. Molecular landscape of BRAF-mutant NSCLC reveals an association between clonality and driver mutations and identifies targetable non-V600 driver mutations. J Thorac Oncol. 2020;15(10):1611-23.
72. 72..
    Takeshima H,Ushijima T. Accumulation of genetic and epigenetic alterations in normal cells and cancer risk. NPJ Precis Oncol. 2019;3:7.
73. 73..
    Li G,Guo X,Chen M,Tang L,Jiang H,Day JX, et al. Prevalence and spec-trum of Akt1, PIK3CA, PTEN and TP53 somatic mutations in Chinese breast cancer patients. PLoS ONE. 2018;13(9):e0203495.
74. 74..
    He F,Zhang F,Liao Y,Tang MS,Wu XR. Structural or functional defects of PTEN in urothelial cells lacking P53 drive basal/squamous-subtype muscle-invasive bladder cancer. Cancer Lett. 2022;550:215924.
75. 75..
    Al Aboud NM,Tupper C,Jialal I. Genetics, epigenetic mechanism. In:StatPearls. Treasure Island (FL): StatPearls Publishing; 2023.
76. 76..
    Evron E,Umbricht CB,Korz D,Raman V,Loeb DM,Niranjan B, et al. Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation1. Cancer Res. 2001;61(6):2782-7.
77. 77..
    Henrique R,Costa VL,Cerveira N,Carvalho AL,Hoque MO,Ribeiro FR, et al. Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer. J Mol Med(Berl). 2006;84(11):911-8.
78. 78..
    Hai R,He L,Shu G,Yin G. Characterization of histone deacetylase mechanisms in cancer development. Front Oncol. 2021;11:700947.
79. 79..
    Vuletić A,Mirjačić Martinović K,Spasić J. Role of histone deacetylase 6 and histone deacetylase 6 inhibition in colorectal cancer. Pharmaceu-tics. 2023;16(1):54.
80. 80..
    Clements ME,Holtslander L,Edwards C,Todd V,Dooyema SDR,Bullock K, et al. HDAC inhibitors induce LIFR expression and promote a dor-mancy phenotype in breast cancer. Oncogene. 2021;40(34):5314-26.
81. 81..
    Edwards CM,Clements ME,3rdVecchi LA,Johnson JA,Johnson RW. HDAC inhibitors stimulate LIFR when it is repressed by hypoxia or PTHrP in breast cancer. J Bone Oncol. 2021;31:100407.
82. 82..
    Hussain MS,Moglad E,Afzal M,Gupta G,Hassan Almalki W,Kazmi I, et al. Non-coding RNA mediated regulation of PI3K/Akt pathway in hepatocellular carcinoma: therapeutic perspectives. Pathol Res Pract.2024;258:155303.
83. 83..
    Watson KL,Jones RA,Bruce A,Moorehead RA. The miR-200b/200a/429 cluster prevents metastasis and induces dormancy in a murine claudin-low mammary tumor cell line. Exp Cell Res. 2018;369(1):17-26.
84. 84..
    Tiram G,Segal E,Krivitsky A,Shreberk-Hassidim R,Ferber S,Ofek P, et al. Identification of dormancy-associated microRNAs for the design of osteosarcoma-targeted dendritic polyglycerol nanopolyplexes. ACS Nano. 2016;10(2):2028-45.
85. 85..
    Tavazoie SF,Alarcón C,Oskarsson T,Padua D,Wang Q,Bos PD, et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature. 2008;451(7175):147-52.
86. 86..
    Almog N,Briggs C,Beheshti A,Ma L,Wilkie KP,Rietman E, et al. Transcriptional changes induced by the tumor dormancy-associated microRNA-190. Transcription. 2013;4(4):177-91.
87. 87..
    Lim PK,Bliss SA,Patel SA,Taborga M,Dave MA,Gregory LA, et al. Gap junction–mediated import of microRNA from bone marrow stromal cells can elicit cell cycle quiescence in breast cancer cells. Cancer Res.2011;71(5):1550-60.
88. 88..
    Moses BS,Evans R,Slone WL,Piktel D,Martinez I,Craig MD, et al. Bone marrow microenvironment niche regulates miR-221/222 in acute lymphoblastic leukemia. Mol Cancer Res. 2016;14(10):909-19.
89. 89..
    Si W,Shen J,Zheng H,Fan W. The role and mechanisms of action of microRNAs in cancer drug resistance. Clin Epigenetics. 2019;11(1):25.
90. 90..
    Han R,Zhao J,Lu L. MicroRNA-34a expression affects breast cancer invasion in vitro and patient survival via downregulation of E2F1 and E2F3 expression. Oncol Rep. 2020;43(6):2062-72.
91. 91..
    Geng D,Song X,Ning F,Song Q,Yin H. MiR-34a inhibits viability and invasion of human papillomavirus-positive cervical cancer cells by targeting E2F3 and regulating survivin. Int J Gynecol Cancer.2015;25(4):707.
92. 92..
    Sanchez Calle A,Yamamoto T,Kawamura Y,Hironaka-Mitsuhashi A,Ono M,Tsuda H, et al. Long non-coding NR2F1-AS1 is associated with tumor recurrence in estrogen receptor-positive breast cancers. Mol Oncol.2020;14(9):2271-87.
93. 93..
    Arun G,Diermeier S,Akerman M,Chang KC,Wilkinson JE,Hearn S, et al. Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss. Genes Dev. 2016;30(1):34-51.
94. 94..
    Huang NS,Chi YY,Xue JY,Liu MY,Huang S,Mo M, et al. Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1(MALAT1) interacts with estrogen receptor and predicted poor survival in breast cancer. Oncotarget. 2016;7(25):37957-65.
95. 95..
    Zhu Y,Hu H,Yuan Z,Zhang Q,Xiong H,Hu Z, et al. LncRNA NEAT1 remodels chromatin to promote the 5-Fu resistance by maintaining colorectal cancer stemness. Cell Death Dis. 2020;11(11):962.
96. 96..
    Zhu L,Zhu Y,Han S,Chen M,Song P,Dai D, et al. Impaired autophagic degradation of lncRNA ARHGAP5-AS1 promotes chemoresistance in gastric cancer. Cell Death Dis. 2019;10(6):383.
97. 97..
    Conigliaro A,Costa V,Lo Dico A,Saieva L,Buccheri S,Dieli F, et al. CD90⁺ liver cancer cells modulate endothelial cell phenotype through the release of exosomes containing H19 lncRNA. Mol Cancer. 2015;14:1-11.
98. 98..
    Kogo R,Shimamura T,Mimori K,Kawahara K,Imoto S,Sudo T, et al. Long noncoding RNA HOTAIR regulates polycomb-dependent chro-matin modification and is associated with poor prognosis in colorectal cancers. Cancer Res. 2011;71(20):6320-6.
99. 99..
    Deng J,Yang M,Jiang R,An N,Wang X,Liu B. Long non-coding RNA HOTAIR regulates the proliferation, self-renewal capacity, tumor formation and migration of the cancer stem-like cell (CSC) subpopulation enriched from breast cancer cells. PLoS One. 2017;12(1):e0170860.
100. 100..
     Gooding AJ,Zhang B,Jahanbani FK,Gilmore HL,Chang JC,Valadkhan S, et al. The lncRNA BORG drives breast cancer metastasis and disease recurrence. Sci Rep. 2017;7(1):12698.
101. 101..
     Gooding AJ,Zhang B,Gunawardane L,Beard A,Valadkhan S,Schie-mann WP. The lncRNA BORG facilitates the survival and chemoresist-ance of triple-negative breast cancers. Oncogene. 2019;38(12):2020-41.
102. 102..
     Xu X,Peng Q,Jiang X,Tan S,Yang Y,Yang W, et al. Metabolic repro-gramming and epigenetic modifications in cancer: from the impacts and mechanisms to the treatment potential. Exp Mol Med.2023;55(7):1357-70.
103. 103..
     Esteller M,Dawson MA,Kadoch C,Rassool FV,Jones PA,Baylin SB. The epigenetic hallmarks of cancer. Cancer Discov. 2024;14(10):1783-809.
104. 104..
     Hou P,Shi P,Jiang T,Yin H,Chu S,Shi M, et al. DKC1 enhances angio-genesis by promoting HIF-1α transcription and facilitates metastasis in colorectal cancer. Br J Cancer. 2020;122(5):668-79.
105. 105..
     Chen YH,Xu NZ,Hong C,Li WQ,Zhang YQ,Yu XY, et al. Myo1b promotes tumor progression and angiogenesis by inhibiting autophagic degradation of HIF-1α in colorectal cancer. Cell Death Dis.2022;13(11):939.
106. 106..
     Zhao T,Zhu Y,Morinibu A,Kobayashi M,Shinomiya K,Itasaka S, et al. HIF-1-mediated metabolic reprogramming reduces ROS levels and facilitates the metastatic colonization of cancers in lungs. Sci Rep.2014;4(1):3793.
107. 107..
     Zeng L,Morinibu A,Kobayashi M,Zhu Y,Wang X,Goto Y, et al. Aberrant IDH3α expression promotes malignant tumor growth by inducing HIF-1-mediated metabolic reprogramming and angiogenesis. Oncogene.2015;34(36):4758-66.
108. 108..
     Deben C,Deschoolmeester V,De Waele J,Jacobs J,Van den Bossche J,Wouters A, et al. Hypoxia-induced cisplatin resistance in non-small cell lung cancer cells is mediated by HIF-1α and mutant p53 and can be overcome by induction of oxidative stress. Cancers. 2018;10(4):126.
109. 109..
     Liu J,Huang X,Liu D,Ji K,Tao C,Zhang R, et al. Demethyleneberberine induces cell cycle arrest and cellular senescence of NSCLC cells via c-Myc/HIF-1α pathway. Phytomedicine. 2021;91:153678.
110. 110..
     Gordan JD,Bertout JA,Hu CJ,Diehl JA,Simon MC. HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell. 2007;11(4):335-47.
111. 111..
     Musleh Ud Din S,Streit SG,Huynh BT,Hana C,Abraham AN,Hussein A. Therapeutic targeting of hypoxia-inducible factors in cancer. Int J Mol Sci. 2024;25(4):2060.
112. 112..
     Ortmann BM. Hypoxia-inducible factor in cancer: from pathway regulation to therapeutic opportunity. BMJ Oncol. 2024;3(1):e000154.
113. 113..
     Mancarella D,Plass C. Epigenetic signatures in cancer: proper controls, current challenges and the potential for clinical translation. Genome Med. 2021;13(1):23.
114. 114..
     Lu Y,Chan YT,Tan HY,Li S,Wang N,Feng Y. Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy. Mol Cancer. 2020;19(1):79.
115. 115..
     Pirozzi CJ,Yan H. The implications of IDH mutations for cancer develop-ment and therapy. Nat Rev Clin Oncol. 2021;18(10):645-61.
116. 116..
     Guo J,Zhang R,Yang Z,Duan Z,Yin D,Zhou Y. Biological roles and therapeutic applications of IDH2 mutations in human cancer. Front Oncol. 2021;11:644857.
117. 117..
     Reitman ZJ,Yan H. Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst. 2010;102(13):932-41.
118. 118..
     Janke R,Iavarone AT,Rine J. Oncometabolite D-2-hydroxyglutarate enhances gene silencing through inhibition of specific H3K36 histone demethylases. Elife. 2017;6:e22451.
119. 119..
     Gavriil M,Proietto M,Paczia N,Ginolhac A,Halder R,Valceschini E, et al. 2-Hydroxyglutarate modulates histone methylation at specific loci and alters gene expression via Rph1 inhibition. Life Sci Alliance.2024;7(2):e202302333.
120. 120..
     Baghban R,Roshangar L,Jahanban-Esfahlan R,Seidi K,Ebrahimi-Kalan A,Jaymand M, et al. Tumor microenvironment complexity and thera-peutic implications at a glance. Cell Commun Signal. 2020;18(1):59.
121. 121..
     Dai L,Li M,Zhang WL,Tang YJ,Tang YL,Liang XH. Fibroblasts in cancer dormancy: FOE or friend? Cancer Cell Int. 2021;21(1):184.
122. 122..
     Parker AL,Cox TR. The role of the ECM in lung cancer dormancy and outgrowth. Front Oncol. 2020;10:1766.
123. 123..
     Kim H,Huber RE,Mahapatra RD,Tseng NH,Peyton SR. Tumor dor-mancy and relapse regulated by the extracellular matrix. In: Leong SP, Nathanson SD, Zager JS, editors. Cancer metastasis through the lymphovascular system. Cham: Springer; 2022. p. 89–96.
124. 124..
     Páez D,Labonte MJ,Bohanes P,Zhang W,Benhanim L,Ning Y, et al. Cancer dormancy: a model of early dissemination and late cancer recurrence. Clin Cancer Res. 2012;18(3):645-53.
125. 125..
     Di Martino JS,Nobre AR,Mondal C,Taha I,Farias EF,Fertig EJ, et al. A tumor-derived type III collagen-rich ECM niche regulates tumor cell dormancy. Nat Cancer. 2022;3(1):90-107.
126. 126..
     Sosa MS,Bragado P,Aguirre-Ghiso JA. Mechanisms of dissemi-nated cancer cell dormancy: an awakening field. Nat Rev Cancer.2014;14(9):611-22.
127. 127..
     Bae SY,Kamalanathan KJ,Galeano-Garces C,Konety BR,Antonarakis ES,Parthasarathy J, et al. Dissemination of circulating tumor cells in breast and prostate cancer: implications for early detection. Endocri-nology. 2024;165(4):bqae022.
128. 128..
     Ring A,Spataro M,Wicki A,Aceto N. Clinical and biological aspects of disseminated tumor cells and dormancy in breast cancer. Front Cell Dev Biol. 2022;10:929893.
129. 129..
     Luzzi KJ,MacDonald IC,Schmidt EE,Kerkvliet N,Morris VL,Chambers AF, et al. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol. 1998;153(3):865-73.
130. 130..
     Kallergi G,Konstantinidis G,Markomanolaki H,Papadaki MA,Mavroudis D,Stournaras C, et al. Apoptotic circulating tumor cells in early and metastatic breast cancer patients. Mol Cancer Ther.2013;12(9):1886-95.
131. 131..
     Spiliotaki M,Mavroudis D,Kapranou K,Markomanolaki H,Kallergi G,Koinis F, et al. Evaluation of proliferation and apoptosis markers in circulating tumor cells of women with early breast cancer who are candidates for tumor dormancy. Breast Cancer Res. 2014;16(6):485.
132. 132..
     Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer. 2007;7(11):834-46.
133. 133..
     Boral D,Liu HN,Kenney SR,Marchetti D. Molecular interplay between dormant bone marrow-resident cells (BMRCs) and CTCs in breast cancer. Cancers. 2020;12(6):1626.
134. 134..
     Emami Nejad A,Najafgholian S,Rostami A,Sistani A,Shojaeifar S,Esparvarinha M, et al. The role of hypoxia in the tumor microenviron-ment and development of cancer stem cell: a novel approach to developing treatment. Cancer Cell Int. 2021;21(1):62.
135. 135..
     Jing X,Yang F,Shao C,Wei K,Xie M,Shen H, et al. Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol Cancer. 2019;18(1):157.
136. 136..
     Shi Y,Lin X,Wang J,Zhou Z,Chen S,Chen G. Advances of HIF-1α/glycolysis axis in non-small cell lung cancer (Review). Oncol Rep.2024;51(4):55.
137. 137..
     Corthay A,Bakacs T,Thangavelu G,Anderson CC. Tackling cancer cell dormancy: insights from immune models, and transplantation. Semin Cancer Biol. 2022;78:5-16.
138. 138..
     Zingoni A,Antonangeli F,Sozzani S,Santoni A,Cippitelli M,Soriani A. The senescence journey in cancer immunoediting. Mol Cancer.2024;23(1):68.
139. 139..
     Peng S,Lin A,Jiang A,Zhang C,Zhang J,Cheng Q, et al. CTLs hetero-geneity and plasticity: implications for cancer immunotherapy. Mol Cancer. 2024;23(1):58.
140. 140..
     Romero I,Garrido F,Garcia-Lora AM. Metastases in immune-mediated dormancy: a new opportunity for targeting cancer. Cancer Res.2014;74(23):6750-7.
141. 141..
     Aqbi HF,Wallace M,Sappal S,Payne KK,Manjili MH. IFN-γ orchestrates tumor elimination, tumor dormancy, tumor escape, and progression. J Leukoc Biol. 2018;103(6):1219-23.
142. 142..
     Jorgovanovic D,Song M,Wang L,Zhang Y. Roles of IFN-γ in tumor progression and regression: a review. Biomark Res. 2020;8:49.
143. 143..
     Mao X,Xu J,Wang W,Liang C,Hua J,Liu J, et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor micro-environment: new findings and future perspectives. Mol Cancer.2021;20(1):131.
144. 144..
     Wu F,Yang J,Liu J,Wang Y,Mu J,Zeng Q, et al. Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer. Signal Transduct Target Ther. 2021;6(1):218.
145. 145..
     Furler RL,Nixon DF,Brantner CA,Popratiloff A,Uittenbogaart CH. TGF-β sustains tumor progression through biochemical and mechanical signal transduction. Cancers (Basel). 2018;10(6):199.
146. 146..
     Stuelten CH,Busch JI,Tang B,Flanders KC,Oshima A,Sutton E, et al. Transient tumor-fibroblast interactions increase tumor cell malignancy by a TGF-beta mediated mechanism in a mouse xenograft model of breast cancer. PLoS One. 2010;5(3):e9832.
147. 147..
     Aspriţoiu VM,Stoica I,Bleotu C,Diaconu CC. Epigenetic regulation of angiogenesis in development and tumors progression: potential implications for cancer treatment. Front Cell Dev Biol. 2021;9:689962.
148. 148..
     Natale G,Bocci G. Tumor dormancy, angiogenesis and metronomic chemotherapy. In: Wang Y, Crea F, editors. Tumor dormancy and recur-rence. Cham: Springer; 2017. p. 31–49.
149. 149..
     Kang Y,Li H,Liu Y,Li Z. Regulation of VEGF-A expression and VEGF-A-targeted therapy in malignant tumors. J Cancer Res Clin Oncol.2024;150(5):1-10.
150. 150..
     Bokhari SM,Hamar P. Vascular endothelial growth factor-D (VEGF-D): an angiogenesis bypass in malignant tumors. Int J Mol Sci.2023;24(17):13317.
151. 151..
     Kang SY,Watnick RS. Regulation of tumor dormancy as a function of tumor-mediated paracrine regulation of stromal Tsp-1 and VEGF expression. APMIS. 2008;116(7–8):638-47.
152. 152..
     Gupta VK,Chaudhuri O. Mechanical regulation of cell-cycle progression and division. Trends Cell Biol. 2022;32(9):773-85.
153. 153..
     Li S,Sampson C,Liu C,Piao HL,Liu HX. Integrin signaling in cancer:bidirectional mechanisms and therapeutic opportunities. Cell Commun Signal. 2023;21(1):266.
154. 154..
     Di Martino JS,Akhter T,Bravo-Cordero JJ. Remodeling the ECM:implications for metastasis and tumor dormancy. Cancers (Basel).2021;13(19):4916.
155. 155..
     Barkan D,Green JE,Chambers AF. Extracellular matrix: a gatekeeper in the transition from dormancy to metastatic growth. Eur J Cancer.2010;46(7):1181-8.
156. 156..
     Redoute-Timonnier C,Auguste P. Implication of the extracellular matrix in metastatic tumor cell dormancy. Cancers. 2024;16(23):4076.
157. 157..
     Bui T,Gu Y,Ancot F,Sanguin-Gendreau V,Zuo D,Muller WJ. Emergence of β1 integrin-deficient breast tumours from dormancy involves both inactivation of p53 and generation of a permissive tumour microenvi-ronment. Oncogene. 2022;41(4):527-37.
158. 158..
     Desgrosellier JS,Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10(1):9-22.
159. 159..
     Baumann K. Mechanotransduction: adhesion forces promote transcription. Nat Rev Mol Cell Biol. 2015;16(7):390.
160. 160..
     Akkoc Y,Peker N,Akcay A,Gozuacik D. Autophagy and cancer dor-mancy. Front Oncol. 2021;11:627023.
161. 161..
     Tiwari M,Srivastava P,Abbas S,Jegatheesan J,Ranjan A,Sharma S, et al. Emerging role of autophagy in governing cellular dormancy, metabolic functions, and therapeutic responses of cancer stem cells. Cells.2024;13(5):447.
162. 162..
     Albrengues J,Shields MA,Ng D,Park CG,Ambrico A,Poindex-ter ME, et al. Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice. Science.2018;361(6409):eaao4227.
163. 163..
     Kikkawa Y,Hozumi K,Katagiri F,Nomizu M,Kleinman HK,Koblin-ski JE. Laminin-111-derived peptides and cancer. Cell Adh Migr.2013;7(1):150-256.
164. 164..
     Lan T,Chen L,Wei X. Inflammatory cytokines in cancer: compre-hensive understanding and clinical progress in gene therapy. Cells.2021;10(1):100.
165. 165..
     Li J,Hubisz MJ,Earlie EM,Duran MA,Hong C,Varela AA, et al. Non-cell-autonomous cancer progression from chromosomal instability. Nature.2023;620(7976):1080-8.
166. 166..
     Hu J,Cao J,Topatana W,Juengpanich S,Li S,Zhang B, et al. Targeting mutant p53 for cancer therapy: direct and indirect strategies. J Hematol Oncol. 2021;14(1):157.
167. 167..
     Wang M,Pan Z,Chu X,Yao X,Duan X,Wan J, et al. Chemotherapy-induced PTEN-L secretion promotes the selection of PTEN-deficient tumor cells. J Exp Clin Cancer Res. 2024;43(1):140.
168. 168..
     Huang MF,Wang YX,Chou YT,Lee DF. Therapeutic strategies for RB1-deficient cancers: intersecting gene regulation and targeted therapy. Cancers (Basel). 2024;16(8):1558.
169. 169..
     Zhu G,Pei L,Xia H,Tang Q,Bi F. Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer. Mol Cancer.2021;20(1):143.
170. 170..
     Dankner M,Rose AAN,Rajkumar S,Siegel PM,Watson IR. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. Oncogene. 2018;37(24):3183-99.
171. 171..
     Hayes DF. HER2 and breast cancer-a phenomenal success story. N Engl J Med. 2019;381(13):1284-6.
172. 172..
     Montalto FI,De Amicis F. Cyclin D1 in cancer: a molecular connection for cell cycle control, adhesion and invasion in tumor and stroma. Cells.2020;9(12):2648.
173. 173..
     Alao JP. The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer.2007;6(1):24.
174. 174..
     Li M,Zhu C,Xue Y,Miao C,He R,Li W, et al. A DNA methylation signature for the prediction of tumour recurrence in stage II colorectal cancer. Br J Cancer. 2023;128(9):1681-9.
175. 175..
     Seligson DB,Horvath S,Shi T,Yu H,Tze S,Grunstein M, et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature. 2005;435(7046):1262-6.
176. 176..
     Zhou M,Xu W,Yue X,Zhao H,Wang Z,Shi H, et al. Relapse-related long non-coding RNA signature to improve prognosis prediction of lung adenocarcinoma. Oncotarget. 2016;7(20):29720-38.
177. 177..
     Feng LY,Chen CX,Li L. Hypermethylation of tumor suppressor genes is a risk factor for poor prognosis in ovarian cancer: a meta-analysis. Medicine. 2019;98(8):e14588.
178. 178..
     Li Z,Zhao B,Qin C,Wang Y,Li T,Wang W. Chromatin dynamics in digestive system cancer: commander and regulator. Front Oncol.2022;12:935877.
179. 179..
     Ruksha TG. MicroRNAs’ control of cancer cell dormancy. Cell Div.2019;14:11.
180. 180..
     Kleivi Sahlberg K,Bottai G,Naume B,Burwinkel B,Calin GA,Børresen-Dale AL, et al. A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients. Clin Cancer Res.2015;21(5):1207-14.
181. 181..
     Kadian LK,Verma D,Lohani N,Yadav R,Ranga S,Gulshan G, et al. Long non-coding RNAs in cancer: multifaceted roles and potential targets for immunotherapy. Mol Cell Biochem. 2024;479(12):3229-54.
182. 182..
     Lodewijk I,Nunes SP,Henrique R,Jerónimo C,Dueñas M,Paramio JM. Tackling tumor microenvironment through epigenetic tools to improve cancer immunotherapy. Clin Epigenetics. 2021;13(1):63.
183. 183..
     Kao TW,Bai GH,Wang TL,Shih IM,Chuang CM,Lo CL, et al. Novel can-cer treatment paradigm targeting hypoxia-induced factor in conjunction with current therapies to overcome resistance. J Exp Clin Cancer Res. 2023;42(1):171.
184. 184..
     Dai L,Xian H,Wang H,Li M,Zhang M,Liang XH, et al. Hypoxia induced cell dormancy of salivary adenoid cystic carcinoma through miR-922/DEC2 axis. Transl Oncol. 2024;40:101868.
185. 185..
     Todoric J,Antonucci L,Karin M. Targeting inflammation in cancer prevention and therapy. Cancer Prev Res (Phila). 2016;9(12):895-905.
186. 186..
     Francescangeli F,De Angelis ML,Baiocchi M,Rossi R,Biffoni M,Zeuner A. COVID-19-induced modifications in the tumor microenvironment:Do they affect cancer reawakening and metastatic relapse? Front Oncol. 2020;10:592891.
187. 187..
     Greten FR,Grivennikov SI. Inflammation and cancer: triggers, mecha-nisms, and consequences. Immunity. 2019;51(1):27-41.
188. 188..
     Sebestyén A,Dankó T,Sztankovics D,Moldvai D,Raffay R,Cervi C, et al. The role of metabolic ecosystem in cancer progression-metabolic plasticity and mTOR hyperactivity in tumor tissues. Cancer Metastasis Rev. 2021;40(4):989-1033.
189. 189..
     Haldar R,Berger LS,Rossenne E,Radin A,Eckerling A,Sandbank E, et al. Perioperative escape from dormancy of spontaneous micro-metastases: a role for malignant secretion of IL-6, IL-8, and VEGF, through adrenergic and prostaglandin signaling. Brain Behav Immun.2023;109:175-87.
190. 190..
     Zhao Y,Shen M,Wu L,Yang H,Yao Y,Yang Q, et al. Stromal cells in the tumor microenvironment: Accomplices of tumor progression? Cell Death Dis. 2023;14(9):587.
191. 191..
     Bussard KM,Mutkus L,Stumpf K,Gomez-Manzano C,Marini FC. Tumor-associated stromal cells as key contributors to the tumor microenviron-ment. Breast Cancer Res. 2016;18(1):84.
192. 192..
     Hill BS,Pelagalli A,Passaro N,Zannetti A. Tumor-educated mesen-chymal stem cells promote pro-metastatic phenotype. Oncotarget.2017;8(42):73296.
193. 193..
     Monteran L,Zait Y,Erez N. It’s all about the base: stromal cells are central orchestrators of metastasis. Trends Cancer. 2024;10(3):208-29.
194. 194..
     Galli F,Aguilera JV,Palermo B,Markovic SN,Nisticò P,Signore A. Rel-evance of immune cell and tumor microenvironment imaging in the new era of immunotherapy. J Exp Clin Cancer Res. 2020;39(1):89.
195. 195..
     Facciabene A,Motz GT,Coukos G. T-regulatory cells: key play-ers in tumor immune escape and angiogenesis. Cancer Res.2012;72(9):2162-71.
196. 196..
     Siddhartha R,Garg M. Interplay between extracellular matrix remodeling and angiogenesis in tumor ecosystem. Mol Cancer Ther.2023;22(3):291-305.
197. 197..
     Prakash J,Shaked Y. The interplay between extracellular matrix remod-eling and cancer therapeutics. Cancer Discov. 2024;14(8):1375-88.
198. 198..
     Henke E,Nandigama R,Ergün S. Extracellular matrix in the tumor microenvironment and its impact on cancer therapy. Front Mol Biosci.2020;6:160.
199. 199..
     de Andrés JL,Griñán-Lisón C,Jiménez G,Marchal JA. Cancer stem cell secretome in the tumor microenvironment: a key point for an effective personalized cancer treatment. J Hematol Oncol. 2020;13(1):136.
200. 200..
     Yang J,Shay C,Saba NF,Teng Y. Cancer metabolism and carcinogenesis. Exp Hematol Oncol. 2024;13(1):10.
201. 201..
     Trajkovic-Arsic M,Subramani E. Is metabolism the magic bullet for targeted cancer therapy?. BMC Cancer. 2023;23(1):484.
202. 202..
     Tufail M,Jiang CH,Li N. Altered metabolism in cancer: insights into energy pathways and therapeutic targets. Mol Cancer. 2024;23(1):203.
203. 203..
     Curry JM,Tuluc M,Whitaker-Menezes D,Ames JA,Anantharaman A,Butera A, et al. Cancer metabolism, stemness and tumor recurrence:MCT1 and MCT4 are functional biomarkers of metabolic symbiosis in head and neck cancer. Cell Cycle. 2013;12(9):1371-84.
204. 204..
     Fiori ME,Di Franco S,Villanova L,Bianca P,Stassi G,De Maria R. Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance. Mol Cancer. 2019;18(1):70.
205. 205..
     Pranzini E,Pardella E,Paoli P,Fendt SM,Taddei ML. Metabolic repro-gramming in anticancer drug resistance: a focus on amino acids. Trends Cancer. 2021;7(8):682-99.
206. 206..
     Cerezo M,Rocchi S. Cancer cell metabolic reprogramming: a keystone for the response to immunotherapy. Cell Death Dis. 2020;11(11):964.
207. 207..
     Marzagalli M,Fontana F,Raimondi M,Limonta P. Cancer stem cells-key players in tumor relapse. Cancers (Basel). 2021;13(3):376.
208. 208..
     Ayob AZ,Ramasamy TS. Cancer stem cells as key drivers of tumour progression. J Biomed Sci. 2018;25(1):20.
209. 209..
     Li Y,Wang Z,Ajani JA,Song S. Drug resistance and cancer stem cells. Cell Commun Signal. 2021;19(1):19.
210. 210..
     Zhou HM,Zhang JG,Zhang X,Li Q. Targeting cancer stem cells for reversing therapy resistance: mechanism, signaling, and prospective agents. Signal Transduct Target Ther. 2021;6(1):62.
211. 211..
     Bhat GR,Sethi I,Sadida HQ,Rah B,Mir R,Algehainy N, et al. Cancer cell plasticity: from cellular, molecular, and genetic mechanisms to tumor heterogeneity and drug resistance. Cancer Metastasis Rev.2024;43(1):197-228.
212. 212..
     Burkhardt DB,San Juan BP,Lock JG,Krishnaswamy S,Chaffer CL. Map-ping phenotypic plasticity upon the cancer cell state landscape using manifold learning. Cancer Discov. 2022;12(8):1847-59.
213. 213..
     Li YR,Fang Y,Lyu Z,Zhu Y,Yang L. Exploring the dynamic interplay between cancer stem cells and the tumor microenvironment: implications for novel therapeutic strategies. J Transl Med. 2023;21(1):686.
214. 214..
     Borlongan MC,Saha D,Wang H. Tumor microenvironment: a niche for cancer stem cell immunotherapy. Stem Cell Rev Rep. 2024;20(1):3-24.
215. 215..
     Tanabe S. Epithelial-mesenchymal transition and cancer stem cells. In:Tanabe S, editor. Cancer stem cell markers and related network path-ways. Cham: Springer; 2022. p. 1–49.
216. 216..
     Glaviano A,Foo ASC,Lam HY,Yap KCH,Jacot W,Jones RH, et al. PI3K/Akt/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 2023;22(1):138.
217. 217..
     Tian LY,Smit DJ,Jücker M. The role of PI3K/Akt/mTOR signaling in hepatocellular carcinoma metabolism. Int J Mol Sci. 2023;24(3):2652.
218. 218..
     Tufail M,Wan WD,Jiang C,Li N. Targeting PI3K/Akt/mTOR signaling to overcome drug resistance in cancer. Chem Biol Interact.2024;396:111055.
219. 219..
     Yu L,Wei J,Liu P. Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer. Semin Cancer Biol.2022;85:69-94.
220. 220..
     Endo H,Okuyama H,Ohue M,Inoue M. Dormancy of cancer cells with suppression of Akt activity contributes to survival in chronic hypoxia. PLoS ONE. 2014;9(6):e98858.
221. 221..
     Shin I,Yakes FM,Rojo F,Shin NY,Bakin AV,Baselga J, et al. PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization. Nat Med.2002;8(10):1145-52.
222. 222..
     Gao Y,Moten A,Lin HK. Akt: a new activation mechanism. Cell Res.2014;24(7):785-6.
223. 223..
     Simons AL,Orcutt KP,Madsen JM,Scarbrough PM,Spitz DR. The role of Akt pathway signaling in glucose metabolism and metabolic oxidative stress. In: Spitz DR, Dornfeld KJ, Krishnan K, Gius D, editors. Oxidative stress in cancer biology and therapy. Totowa: Humana Press; 2012. p. 21–46.
224. 224..
     Bose S,Le A. Glucose metabolism in cancer. In: Le A, editor. The heterogeneity of cancer metabolism. Cham: Springer; 2018. p. 3–12.
225. 225..
     Hosios AM,Manning BD. Cancer signaling drives cancer metabolism:AKT and the Warburg effect. Cancer Res. 2021;81(19):4896-8.
226. 226..
     You B,Xia T,Gu M,Zhang Z,Zhang Q,Shen J, et al. AMPK-mTOR-mediated activation of autophagy promotes formation of dormant polyploid giant cancer cells. Cancer Res. 2022;82(5):846-58.
227. 227..
     Sun Y,Chen Y,Liu Z,Wang J,Bai J,Du R, et al. Mitophagy-mediated tumor dormancy protects cancer cells from chemotherapy. Biomedi-cines. 2024;12(2):305.
228. 228..
     Tiwari A,Trivedi R,Lin SY. Tumor microenvironment: barrier or oppor-tunity towards effective cancer therapy. J Biomed Sci. 2022;29(1):83.
229. 229..
     Bu L,Wang H,Pan JA,Chen L,Xing F,Wu J, et al. PTEN suppresses tumorigenesis by directly dephosphorylating Akt. Signal Transduct Target Ther. 2021;6(1):262.
230. 230..
     Phin S,Moore M,Cotter PD. Genomic rearrangements of PTEN in prostate cancer. Front Oncol. 2013;3:240.
231. 231..
     Tufail M,Hu JJ,Liang J,He CY,Wan WD,Huang YQ, et al. Predictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway. J Transl Med. 2024;22(1):15.
232. 232..
     Russo M,Nastasi C. Targeting the tumor microenvironment: a close up of tumor-associated macrophages and neutrophils. Front Oncol.2022;12:871513.
233. 233..
     Tufail M,Hu JJ,Liang J,He CY,Wan WD,Huang YQ, et al. Hallmarks of cancer resistance. iScience. 2024;27(6):109979.
234. 234..
     Ye Y,Wang J,Dillard J,Barsky SH. Tumor dormancy within the lym-phovascular embolus is regulated by multiple metabolism-signaling pathways. Anticancer Res. 2024;44(10):4165.
235. 235..
     Owonikoko TK,Khuri FR. Targeting the PI3K/Akt/mTOR pathway:biomarkers of success and tribulation. Am Soc Clin Oncol Educ Book.2013. .
236. 236..
     Trigueiros B,Santos IJS,Pimenta FP,Ávila AR. A long way to go: a scenario for clinical trials of PI3K inhibitors in treating cancer. Cancer Control. 2024;31:10732748241238048.
237. 237..
     Zelenetz AD,Brown JR,Delgado J,Eradat H,Ghia P,Jacob A, et al. Updated analysis of overall survival in randomized phase III study of idelalisib in combination with bendamustine and rituximab in patients with relapsed/refractory CLL. Blood. 2016;128(22):231.
238. 238..
     Savas P,Lo LL,Luen SJ,Blackley EF,Callahan J,Moodie K, et al. Alpelisib monotherapy for PI3K-altered, pretreated advanced breast cancer: a phase II study. Cancer Discov. 2022;12(9):2058-73.
239. 239..
     Lin X,Han L,Weng J,Wang K,Chen T. Rapamycin inhibits proliferation and induces autophagy in human neuroblastoma cells. Biosci Rep.2018;38(6):BSR20181822.
240. 240..
     Wang Z,Wang X,Cheng F,Wen X,Feng S,Yu F, et al. Rapamycin inhib-its glioma cells growth and promotes autophagy by miR-26a-5p/DAPK1 axis. Cancer Manag Res. 2021;13:2691-700.
241. 241..
     Aguirre-Ghiso JA,Estrada Y,Liu D,Ossowski L. ERKMAPK activity as a determinant of tumor growth and dormancy; regulation by p38SAPK1. Cancer Res. 2003;63(7):1684-95.
242. 242..
     Deschênes-Simard X,Malleshaiah M,Ferbeyre G. Extracellular signal-regulated kinases: one pathway, multiple fates. Cancers (Basel).2024;16(1):95.
243. 243..
     Crozet F,Levayer R. Emerging roles and mechanisms of ERK pathway mechanosensing. Cell Mol Life Sci. 2023;80(12):355.
244. 244..
     Luo Z,Tian M,Yang G,Tan Q,Chen Y,Li G, et al. Hypoxia signaling in human health and diseases: implications and prospects for therapeu-tics. Signal Transduct Target Ther. 2022;7(1):218.
245. 245..
     Sugiura R,Satoh R,Takasaki T. ERK: a double-edged sword in cancer. ERK-dependent apoptosis as a potential therapeutic strategy for cancer. Cells. 2021;10(10):2509.
246. 246..
     Shin S,Buel GR,Wolgamott L,Plas DR,Asara JM,Blenis J, et al. ERK2 mediates metabolic stress response to regulate cell fate. Mol Cell.2015;59(3):382-98.
247. 247..
     Zhang M,Bai Y,Xu C,Qi Y,Meng J,Zhang W, et al. Blockage of extracel-lular signal-regulated kinase exerts an antitumor effect via regulating energy metabolism and enhances the efficacy of autophagy inhibitors by regulating transcription factor EB nuclear translocation in osteosar-coma. Front Cell Dev Biol. 2021;9:650846.
248. 248..
     Martinez-Lopez N,Athonvarangkul D,Mishall P,Sahu S,Singh R. Autophagy proteins regulate ERK phosphorylation. Nat Commun.2013;4:2799.
249. 249..
     Ossowski L,Aguirre Ghiso J,Liu D,Estrada Y,Rosenbaum S. The role of ERK and p38 in regulation of tumor dormancy. Cancer Res.2004;64(7_supplement):1318-9.
250. 250..
     Sosa MS,Bragado P,Debnath J,Aguirre-Ghiso JA. Regulation of tumor cell dormancy by tissue microenvironments and autophagy. In: Ender-ling H, Almog N, Hlatky L, editors. Systems biology of tumor dormancy. New York: Springer; 2013. p. 73–89.
251. 251..
     Bahar ME,Kim HJ,Kim DR. Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies. Signal Transduct Target Ther. 2023;8(1):455.
252. 252..
     Jaiswal BS,Durinck S,Stawiski EW,Yin J,Wang W,Lin E, et al. ERK mutations and amplification confer resistance to ERK-inhibitor therapy. Clin Cancer Res. 2018;24(16):4044-55.
253. 253..
     Morris RM,Mortimer TO,O’Neill KL. Cytokines: can cancer get the mes-sage? Cancers (Basel). 2022;14(9):2178.
254. 254..
     Dunlop RJ,Campbell CW. Cytokines and advanced cancer. J Pain Symp-tom Manage. 2000;20(3):214-32.
255. 255..
     Kciuk M,Gielecińska A,Budzinska A,Mojzych M,Kontek R. Metastasis and MAPK pathways. Int J Mol Sci. 2022;23(7):3847.
256. 256..
     Yuan J,Dong X,Yap J,Hu J. The MAPK and AMPK signalings: inter-play and implication in targeted cancer therapy. J Hematol Oncol.2020;13(1):113.
257. 257..
     Ali ES,Akter S,Ramproshad S,Mondal B,Riaz TA,Islam MT, et al. Targeting Ras-ERK cascade by bioactive natural products for potential treat-ment of cancer: an updated overview. Cancer Cell Int. 2022;22(1):246.
258. 258..
     Eleveld TF,Oldridge DA,Bernard V,Koster J,Colmet Daage L,Diskin SJ, et al. Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nat Genet. 2015;47(8):864-71.
259. 259..
     Roy S,Roy S,Kar M,Padhi S,Saha A,Anuja K, et al. Role of p38 MAPK in disease relapse and therapeutic resistance by maintenance of cancer stem cells in head and neck squamous cell carcinoma. J Oral Pathol Med. 2018;47(5):492-501.
260. 260..
     Qi F,Wang Y,Yu B,Li F. Identification of RECK as a protective prognostic indicator and a tumor suppressor through regulation of the ERK/MAPK signaling pathway in gastric cancer. J Transl Med. 2023;21(1):766.
261. 261..
     Sanchez JN,Wang T,Cohen MS. BRAF and MEK inhibitors: use and resistance in BRAF-mutated cancers. Drugs. 2018;78(5):549-66.
262. 262..
     Subbiah V,Baik C,Kirkwood JM. Clinical development of BRAF plus MEK inhibitor combinations. Trends Cancer. 2020;6(9):797-810.
263. 263..
     Shang S,Hua F,Hu ZW. The regulation of β-catenin activity and function in cancer: therapeutic opportunities. Oncotarget.2017;8(20):33972-89.
264. 264..
     Wen X,Wu Y,Awadasseid A,Tanaka Y,Zhang W. New advances in canonical Wnt/β-catenin signaling in cancer. Cancer Manag Res.2020;12:6987-98.
265. 265..
     Liu J,Xiao Q,Xiao J,Niu C,Li Y,Zhang X, et al. Wnt/β-catenin signalling:function, biological mechanisms, and therapeutic opportunities. Signal Transduct Target Ther. 2022;7(1):3.
266. 266..
     Zhang Y,Wang X. Targeting the Wnt/β-catenin signaling pathway in cancer. J Hematol Oncol. 2020;13(1):165.
267. 267..
     Lecarpentier Y,Schussler O,Hébert JL,Vallée A. Multiple targets of the canonical Wnt/β-catenin signaling in cancers. Front Oncol. 2019;9:1248.
268. 268..
     Mo Y,Wang Y,Zhang L,Yang L,Zhou M,Li X, et al. The role of Wnt signaling pathway in tumor metabolic reprogramming. J Cancer.2019;10(16):3789-97.
269. 269..
     Rasmussen ML,Ortolano NA,Romero-Morales AI,Gama V. Wnt signaling and its impact on mitochondrial and cell cycle dynamics in pluripotent stem cells. Genes (Basel). 2018;9(2):109.
270. 270..
     Zhang Y,Pizzute T,Pei M. A review of crosstalk between MAPK and Wnt signals and its impact on cartilage regeneration. Cell Tissue Res.2014;358(3):633-49.
271. 271..
     Patel S,Alam A,Pant R,Chattopadhyay S. Wnt signaling and its signifi-cance within the tumor microenvironment: novel therapeutic insights. Front Immunol. 2019;10:2872.
272. 272..
     Ruan Y,Ogana H,Gang E,Kim HN,Kim YM. Wnt signaling in the tumor microenvironment. In: Birbrair A, editor. Tumor microenvironment:signaling pathways—part B. Cham: Springer; 2021. p. 107–21.
273. 273..
     Sharma A,Mir R,Galande S. Epigenetic regulation of the Wnt/β-catenin signaling pathway in cancer. Front Genet. 2021;12:681053.
274. 274..
     Costa VL,Henrique R,Ribeiro FR,Carvalho JR,Oliveira J,Lobo F, et al. Epigenetic regulation of Wnt signaling pathway in urological cancer. Epigenetics. 2010;5(4):343-51.
275. 275..
     Jere SW,Abrahamse H,Houreld NN. Interaction of the Akt and β-catenin signalling pathways and the influence of photobiomodulation on cellular signalling proteins in diabetic wound healing. J Biomed Sci. 2023;30(1):81.
276. 276..
     Choi JH,Jang TY,Jeon SE,Kim JH,Lee CJ,Yun HJ, et al. The small-molecule Wnt inhibitor ICG-001 efficiently inhibits colorectal cancer stemness and metastasis by suppressing MEIS1 expression. Int J Mol Sci. 2021;22(24):13413.
277. 277..
     Sasaki T,Hwang H,Nguyen C,Kloner RA,Kahn M. The small molecule Wnt signaling modulator ICG-001 improves contractile function in chronically infarcted rat myocardium. PLoS One. 2013;8(9):e75010.
278. 278..
     Merikhian P,Eisavand MR,Farahmand L. Triple-negative breast cancer:understanding Wnt signaling in drug resistance. Cancer Cell Int.2021;21(1):419.
279. 279..
     Mortezaee K. WNT/β-catenin regulatory roles on PD-(L)1 and immuno-therapy responses. Clin Exp Med. 2024;24(1):15.
280. 280..
     Krishnamurthy N,Kurzrock R. Targeting the Wnt/beta-catenin pathway in cancer: update on effectors and inhibitors. Cancer Treat Rev.2018;62:50-60.
281. 281..
     Sriuranpong V,Borges MW,Ravi RK,Arnold DR,Nelkin BD,Baylin SB, et al. Notch signaling induces cell cycle arrest in small cell lung cancer cells1. Cancer Res. 2001;61(7):3200-5.
282. 282..
     Rao SS,O’Neil J,Liberator CD,Hardwick JS,Dai X,Zhang T, et al. Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells. Cancer Res. 2009;69(7):3060-8.
283. 283..
     Abravanel DL,Belka GK,Pan TC,Pant DK,Collins MA,Sterner CJ, et al. Notch promotes recurrence of dormant tumor cells following HER2/neu-targeted therapy. J Clin Invest. 2015;125(6):2484-96.
284. 284..
     Capulli M,Hristova D,Valbret Z,Carys K,Arjan R,Maurizi A, et al. Notch2 pathway mediates breast cancer cellular dormancy and mobilisation in bone and contributes to haematopoietic stem cell mimicry. Br J Cancer.2019;121(2):157-71.
285. 285..
     Kipper FC,Kieran MW,Thomas A,Panigrahy D. Notch signaling in malig-nant gliomas: supporting tumor growth and the vascular environment. Cancer Metastasis Rev. 2022;41(3):737-47.
286. 286..
     Bigas A,Porcheri C. Notch and Stem Cells. In: Borggrefe T, Giaimo BD, editors. Molecular mechanisms of notch signaling. Cham: Springer;2018. p. 235–63.
287. 287..
     Xiao W,Gao Z,Duan Y,Yuan W,Ke Y. Notch signaling plays a crucial role in cancer stem-like cells maintaining stemness and mediating chemot-axis in renal cell carcinoma. J Exp Clin Cancer Res. 2017;36(1):41.
288. 288..
     Bocci F,Onuchic JN,Jolly MK. Understanding the principles of pattern formation driven by Notch signaling by integrating experiments and theoretical models. Front Physiol. 2020;11:929.
289. 289..
     D’Assoro AB,Leon-Ferre R,Braune EB,Lendahl U. Roles of Notch signaling in the tumor microenvironment. Int J Mol Sci. 2022;23(11):6241.
290. 290..
     Li X,Yan X,Wang Y,Kaur B,Han H,Yu J. The Notch signaling path-way: a potential target for cancer immunotherapy. J Hematol Oncol.2023;16(1):45.
291. 291..
     Bhagat TD,Zou Y,Huang S,Park J,Palmer MB,Hu C, et al. Notch path-way is activated via genetic and epigenetic alterations and is a thera-peutic target in clear cell renal cancer. J Biol Chem. 2017;292(3):837-46.
292. 292..
     Schott AF,Landis MD,Dontu G,Griffith KA,Layman RM,Krop I, et al. Preclinical and clinical studies of gamma secretase inhibitors with doc-etaxel on human breast tumors. Clin Cancer Res. 2013;19(6):1512-24.
293. 293..
     Gharaibeh L,Elmadany N,Alwosaibai K,Alshaer W. Notch1 in cancer therapy: possible clinical implications and challenges. Mol Pharmacol.2020;98(5):559-76.
294. 294..
     Illimoottil M,Ginat D. Recent advances in deep learning and medical imaging for head and neck cancer treatment: MRI, CT, and PET scans. Cancers (Basel). 2023;15(13):3267.
295. 295..
     Schwenck J,Sonanini D,Cotton JM,Rammensee HG,la Fougère C,Zender L, et al. Advances in PET imaging of cancer. Nat Rev Cancer.2023;23(7):474-90.
296. 296..
     Overcast WB,Davis KM,Ho CY,Hutchins GD,Green MA,Graner BD, et al. Advanced imaging techniques for neuro-oncologic tumor diagnosis, with an emphasis on PET-MRI imaging of malignant brain tumors. Curr Oncol Rep. 2021;23(3):34.
297. 297..
     Mohamed MM,Mahesh TR,Vinoth KV,Guluwadi S. Enhancing brain tumor detection in MRI images through explainable AI using Grad-CAM with Resnet 50. BMC Med Imaging. 2024;24(1):107.
298. 298..
     Zhong X,Zhang H,Zhu Y,Liang Y,Yuan Z,Li J, et al. Circulating tumor cells in cancer patients: developments and clinical applications for immunotherapy. Mol Cancer. 2020;19(1):15.
299. 299..
     Lin D,Shen L,Luo M,Zhang K,Li J,Yang Q, et al. Circulating tumor cells: biology and clinical significance. Signal Transduct Target Ther.2021;6(1):404.
300. 300..
     Lee Y,El Andaloussi S,Wood MJ. Exosomes and microvesicles: extracel-lular vesicles for genetic information transfer and gene therapy. Hum Mol Genet. 2012;21(R1):R125-34.
301. 301..
     Gurung S,Perocheau D,Touramanidou L,Baruteau J. The exosome journey: from biogenesis to uptake and intracellular signalling. Cell Commun Signal. 2021;19(1):47.
302. 302..
     Essola JM,Zhang M,Yang H,Li F,Xia B,Mavoungou JF, et al. Exosome regulation of immune response mechanism: pros and cons in immuno-therapy. Bioact Mater. 2024;32:124-46.
303. 303..
     Kugeratski FG,Kalluri R. Exosomes as mediators of immune regulation and immunotherapy in cancer. FEBS J. 2021;288(1):10-35.
304. 304..
     Chen XM,Wang X,Hou Z. MSC-derived exosomes in tissue regeneration. Front Cell Dev Biol. 2023;11:1293109.
305. 305..
     Zhang M,Wan L,Li R,Li X,Zhu T,Lu H. Engineered exosomes for tissue regeneration: from biouptake, functionalization, biosafety to applications. Biomater Sci. 2023;11(22):7247-67.
306. 306..
     Tan F,Li X,Wang Z,Li J,Shahzad K,Zheng J. Clinical applications of stem cell-derived exosomes. Signal Transduct Target Ther. 2024;9(1):17.
307. 307..
     Riau AK,Ong HS,Yam GHF,Mehta JS. Sustained delivery system for stem cell-derived exosomes. Front Pharmacol. 2019;10:1368.
308. 308..
     Zhang L,Mao L,Wang H. The neuroprotection effects of exosome in central nervous system injuries: a new target for therapeutic intervention. Mol Neurobiol. 2022;59(12):7152-69.
309. 309..
     Fan Y,Chen Z,Zhang M. Role of exosomes in the pathogenesis, diag-nosis, and treatment of central nervous system diseases. J Transl Med.2022;20(1):291.
310. 310..
     Røsand Ø,Høydal MA. Cardiac exosomes in ischemic heart disease-a narrative review. Diagnostics (Basel). 2021;11(2):269.
311. 311..
     Zamani P,Fereydouni N,Butler AE,Navashenaq JG,Sahebkar A. The therapeutic and diagnostic role of exosomes in cardiovascular diseases. Trends Cardiovasc Med. 2019;29(6):313-23.
312. 312..
     Huber CC,Wang H. Pathogenic and therapeutic role of exosomes in neurodegenerative disorders. Neural Regen Res. 2024;19(1):75-9.
313. 313..
     Nouri Z,Barfar A,Perseh S,Motasadizadeh H,Maghsoudian S,Fatahi Y, et al. Exosomes as therapeutic and drug delivery vehicle for neurode-generative diseases. J Nanobiotechnol. 2024;22(1):463.
314. 314..
     Ghosh S,Rajendran RL,Mahajan AA,Chowdhury A,Bera A,Guha S, et al. Harnessing exosomes as cancer biomarkers in clinical oncology. Cancer Cell Int. 2024;24(1):278.
315. 315..
     Luo S,Chen J,Xu F,Chen H,Li Y,Li W. Dendritic cell-derived exosomes in cancer immunotherapy. Pharmaceutics. 2023;15(8):2070.
316. 316..
     Chen N,Wang YL,Sun HF,Wang ZY,Zhang Q,Fan FY, et al. Potential regulatory effects of stem cell exosomes on inflammatory response in ischemic stroke treatment. World J Stem Cells. 2023;15(6):561.
317. 317..
     Tian CM,Yang MF,Xu HM,Zhu MZ,Zhang Y,Yao J, et al. Mesenchymal stem cell-derived exosomes: novel therapeutic approach for inflamma-tory bowel diseases. Stem Cells Int. 2023;2023(1):4245704.
318. 318..
     Yumoto K,Berry JE,Taichman RS,Shiozawa Y. A novel method for moni-toring tumor proliferation in vivo using fluorescent dye DiD. Cytom A.2014;85(6):548-55.
319. 319..
     Tobata H,Nagashima K,Okazaki Y,Sagawa T. Chiral stacking of cyanine or porphyrin as cationic fluorescent dyes in the presence of anionic polysaccharide of hyaluronic acid. SN Appl Sci. 2020;2(2):253.
320. 320..
     Wang K,Du Y,Zhang Z,He K,Cheng Z,Yin L, et al. Fluorescence image-guided tumour surgery. Nat Rev Bioeng. 2023;1(3):161-79.
321. 321..
     Jenkins R,Burdette MK,Foulger SH. Mini-review: fluorescence imaging in cancer cells using dye-doped nanoparticles. RSC Adv.2016;6(70):65459-74.
322. 322..
     Close DM,Xu T,Sayler GS,Ripp S. In vivo bioluminescent imaging (BLI):noninvasive visualization and interrogation of biological processes in living animals. Sensors. 2010;11(1):180-206.
323. 323..
     Choy G,O’Connor S,Diehn FE,Costouros N,Alexander HR,Choyke P, et al. Comparison of noninvasive fluorescent and bioluminescent small animal optical imaging. Biotechniques. 2003;35(5):1022-30.
324. 324..
     Shachaf CM,Felsher DW. Tumor dormancy and MYC inactivation: pushing cancer to the brink of normalcy. Cancer Res. 2005;65(11):4471-4.
325. 325..
     Mali SB. Bioluminescence in cancer research—applications and chal-lenges. Oral Oncol Rep. 2023;9:100127.
326. 326..
     Satam H,Joshi K,Mangrolia U,Waghoo S,Zaidi G,Rawool S, et al. Next-generation sequencing technology: current trends and advancements. Biology (Basel). 2023;12(7):997.
327. 327..
     Marchetti F,Cardoso R,Chen CL,Douglas GR,Elloway J,Escobar PA, et al. Error-corrected next generation sequencing-promises and chal-lenges for genotoxicity and cancer risk assessment. Mutat Res Rev Mutat Res. 2023;792:108466.
328. 328..
     de Biase D,Fassan M,Malapelle U. Next-generation sequencing in tumor diagnosis and treatment. Diagnostics (Basel). 2020;10(11):962.
329. 329..
     Cho J,Min HY,Lee HJ,Hyun SY,Sim JY,Noh M, et al. RGS2-mediated translational control mediates cancer cell dormancy and tumor relapse. J Clin Invest. 2023;133(10):e171901.
330. 330..
     Welch DR. Dormancy in cancer metastasis: keys to moving forward. Cancer Metastasis Rev. 2023;42(1):5-7.
331. 331..
     Cui M,Cheng C,Zhang L. High-throughput proteomics: a methodo-logical mini-review. Lab Invest. 2022;102(11):1170-81.
332. 332..
     Zhou Y,Lih TM,Pan J,Höti N,Dong M,Cao L, et al. Proteomic signatures of 16 major types of human cancer reveal universal and cancer-type-specific proteins for the identification of potential therapeutic targets. J Hematol Oncol. 2020;13(1):170.
333. 333..
     Hanash S,Schliekelman M. Proteomic profiling of the tumor microenvi-ronment: recent insights and the search for biomarkers. Genome Med.2014;6(2):12.
334. 334..
     Almog N,Klement GL. Platelet proteome and tumor dormancy: can platelets content serve as predictive biomarkers for exit of tumors from dormancy?. Cancers (Basel). 2010;2(2):842-58.
335. 335..
     Xu J,Liao K,Yang X,Wu C,Wu W. Using single-cell sequencing technol-ogy to detect circulating tumor cells in solid tumors. Mol Cancer.2021;20(1):104.
336. 336..
     Ren Q,Khoo WH,Corr AP,Phan TG,Croucher PI,Stewart SA. Gene expression predicts dormant metastatic breast cancer cell phenotype. Breast Cancer Res. 2022;24(1):10.
337. 337..
     Elkholi IE,Lalonde A,Park M,Côté JF. Breast cancer metastatic dor-mancy and relapse: an enigma of microenvironment(s). Cancer Res.2022;82(24):4497-510.
338. 338..
     Razavipour SF,Harikumar KB,Slingerland JM. p27 as a transcriptional regulator: new roles in development and cancer. Cancer Res.2020;80(17):3451-8.
339. 339..
     Cascardo F,Vivanco M,Perrone MC,Werbach A,Enrico D,Mando P, et al. Higher risk of recurrence in early-stage breast cancer patients with increased levels of ribosomal protein S6. Sci Rep. 2024;14(1):25136.
340. 340..
     Chandhanayingyong C,Kim Y,Staples JR,Hahn C,Lee FY. MAPK/ERK signaling in osteosarcomas, ewing sarcomas and chondrosar-comas: therapeutic implications and future directions. Sarcoma.2012;2012(1):404810.
341. 341..
     McLean ME,MacLean MR,Cahill HF,Arun RP,Walker OL,Wasson MD, et al. The expanding role of cancer stem cell marker ALDH1A3 in cancer and beyond. Cancers (Basel). 2023;15(2):492.
342. 342..
     Zheng Q,Zhang M,Zhou F,Zhang L,Meng X. The breast cancer stem cells traits and drug resistance. Front Pharmacol. 2021;11:599965.
343. 343..
     Addanki S,Meas S,Sarli VN,Singh B,Lucci A. Applications of circulating tumor cells and circulating tumor DNA in precision oncology for breast cancers. Int J Mol Sci. 2022;23(14):7843.
344. 344..
     Magbanua MJM,Li W,van’t Veer LJ. Integrating imaging and circulating tumor DNA features for predicting patient outcomes. Cancers (Basel).2024;16(10):1879.
345. 345..
     Coombes RC,Page K,Salari R,Hastings RK,Armstrong A,Ahmed S, et al. Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence. Clin Cancer Res. 2019;25(14):4255-63.
346. 346..
     García-Pardo M,Makarem M,Li JJN,Kelly D,Leighl NB. Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportuni-ties and challenges. Br J Cancer. 2022;127(4):592-602.
347. 347..
     Liu C,Tang H,Hu N,Li T. Methylomics and cancer: the current state of methylation profiling and marker development for clinical care. Cancer Cell Int. 2023;23(1):242.
348. 348..
     Ilango S,Paital B,Jayachandran P,Padma PR,Nirmaladevi R. Epigenetic alterations in cancer. Front Biosci (Landmark Ed). 2020;25(6):1058-109.
349. 349..
     Zhen L,Liu X,Yegang C,Yongjiao Y,Yawei X,Jiaqi K, et al. Accuracy of multiparametric magnetic resonance imaging for diagnosing prostate Cancer: a systematic review and meta-analysis. BMC Cancer.2019;19(1):1244.
350. 350..
     Harsini S,Bénard F. PET imaging in clinical oncology. In: Rezaei N, editor. Handbook of cancer and immunology. Cham: Springer; 2022. p. 1–26.
351. 351..
     Wang K,Li Z,Wu Z,Zheng Y,Zeng S, et al. Diagnostic performance of diffusion tensor imaging for characterizing breast tumors: a compre-hensive meta-analysis. Front Oncol. 2019;9:1229.
352. 352..
     Urut DU,Karabulut D,Hereklioglu S,Özdemir G,Cicin BA,Hacıoglu B, et al. Diffusion tensor imaging: survival analysis prediction in breast cancer patients. Radiologie (Heidelb). 2024;64(Suppl 1):54-9.
353. 353..
     Ganiyani MA,Prabhakar P,Khosla AA,Bellur SS,Pon Avudaiappan A,Bond L, et al. Impact of TP53, RB1, and PTEN mutations on overall survival in metastatic prostate cancer: a multi-center study via the Guardian Research Network. J Clin Oncol. 2024;42(4_suppl):82.
354. 354..
     Løes IM,Immervoll H,Sorbye H,Angelsen JH,Horn A,Knappskog S, et al. Impact of KRAS, BRAF, PIK3CA, TP53 status and intra individual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases. Int J Cancer. 2016;139(3):647-56.
355. 355..
     Li S,Silvestri V,Leslie G,Rebbeck TR,Neuhausen SL,Hopper JL, et al. Cancer risks associated with BRCA1 and BRCA2 pathogenic variants. J Clin Oncol. 2022;40(14):1529-41.
356. 356..
     Retèl VP,Groothuis-Oudshoorn CG,Aaronson NK,Brewer NT,Rutgers EJ,van Harten WH. Association between genomic recurrence risk and well-being among breast cancer patients. BMC Cancer. 2013;13(1):295.
357. 357..
     Wang G,Xu D,Zhang Z,Li X,Shi J,Sun J, et al. The pan-cancer land-scape of crosstalk between epithelial-mesenchymal transition and immune evasion relevant to prognosis and immunotherapy response. NPJ Precis Oncol. 2021;5(1):56.
358. 358..
     Li QJ,Wu ZL,Wang J,Jiang J,Lin B. An EMT-based gene signature enhances the clinical understanding and prognostic prediction of patients with ovarian cancers. J Ovarian Res. 2023;16(1):51.
359. 359..
     Meng J,Chen S,Han JX,Qian B,Wang XR,Zhong WL, et al. Twist1 regu-lates vimentin through Cul2 circular RNA to promote EMT in hepatocel-lular carcinoma. Cancer Res. 2018;78(15):4150-62.
360. 360..
     Huang X,Xiang L,Wang B,Hu J,Liu C,Ren A, et al. CMTM6 promotes migration, invasion, and EMT by interacting with and stabilizing vimen-tin in hepatocellular carcinoma cells. J Transl Med. 2021;19:1-15.
361. 361..
     Zhang Y,Cao N,Gao J,Liang J,Liang Y,Xie Y, et al. ASIC1a stimulates the resistance of human hepatocellular carcinoma by promoting EMT via the AKT/GSK3β/Snail pathway driven by TGFβ/Smad signals. J Cell Mol Med. 2022;26(10):2777-92.
362. 362..
     Bao Z,Zeng W,Zhang D,Wang L,Deng X,Lai J, et al. SNAIL induces EMT and lung metastasis of tumours secreting CXCL2 to promote the inva-sion of M2-type immunosuppressed macrophages in colorectal cancer. Int J Biol Sci. 2022;18(7):2867.
363. 363..
     Jin L,Zhang J,Fu HQ,Zhang X,Pan YL. FOXO3a inhibits the EMT and metastasis of breast cancer by regulating TWIST-1 mediated miR-10b/CADM2 axis. Transl Oncol. 2021;14(7):101096.
364. 364..
     Song Y,Zhang W,Zhang J,You Z,Hu T,Shao G, et al. TWIST2 inhibits EMT and induces oxidative stress in lung cancer cells by regulating the FGF21-mediated AMPK/mTOR pathway. Exp Cell Res.2021;405(1):112661.
365. 365..
     Vimalraj S. A concise review of VEGF, PDGF, FGF, Notch, angiopoi-etin, and HGF signalling in tumor angiogenesis with a focus on alternative approaches and future directions. Int J Biol Macromol.2022;221:1428-38.
366. 366..
     Li X,Li H,Li Z,Wang T,Yu D,Jin H, et al. TRPV3 promotes the angio-genesis through HIF-1α-VEGF signaling pathway in A549 cells. Acta Histochem. 2022;124(8):151955.
367. 367..
     Deng Y,Xia X,Zhao Y,Zhao Z,Martinez C,Yin W, et al. Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to pro-mote immune evasion and immunotherapy resistance. Nat Commun.2021;12(1):7041.
368. 368..
     Bao S,Jiang X,Jin S,Tu P,Lu J. TGF-β1 induces immune escape by enhancing PD-1 and CTLA-4 expression on T lymphocytes in hepato-cellular carcinoma. Front Oncol. 2021;11:694145.
369. 369..
     Xu W,He Y,Wang Y,Li X,Young J,Ioannidis JPA, et al. Risk factors and risk prediction models for colorectal cancer metastasis and recurrence: an umbrella review of systematic reviews and meta-analyses of observational studies. BMC Med. 2020;18(1):172.
370. 370..
     Curigliano G,Dent R,Llombart-Cussac A,Pegram M,Pusztai L,Turner N, et al. Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR⁺/HER2^- breast cancer. NPJ Breast Cancer. 2023;9(1):56.
371. 371..
     Kwon MJ. Predictive biomarkers for molecularly targeted thera-pies and immunotherapies in breast cancer. Arch Pharm Res.2022;45(9):597-617.
372. 372..
     Foser S,Maiese K,Digumarthy SR,Puig-Butille JA,Rebhan C. Looking to the future of early detection in cancer: liquid biopsies, imaging, and artificial intelligence. Clin Chem. 2024;70(1):27-32.
373. 373..
     Liang MX,Fei YJ,Yang K,Tang WJ,Cao XH,Tang JH. Potential values of circulating tumor cell for detection of recurrence in patients of thyroid cancer: a diagnostic meta-analysis. BMC Cancer. 2022;22(1):954.
374. 374..
     Zhou S,Xu H,Duan Y,Tang Q,Huang H,Bi F. Survival mechanisms of cir-culating tumor cells and their implications for cancer treatment. Cancer Metastasis Rev. 2024;43(3):941-57.
375. 375..
     Yan YY,Guo QR,Wang FH,Adhikari R,Zhu ZY,Zhang HY, et al. Cell-free DNA: hope and potential application in cancer. Front Cell Dev Biol.2021;9: 639233.
376. 376..
     Tian W,Lei N,Zhou J,Chen M,Guo R,Qin B, et al. Extracellular vesicles in ovarian cancer chemoresistance, metastasis, and immune evasion. Cell Death Dis. 2022;13(1):64.
377. 377..
     Nguyen TNA,Huang PS,Chu PY,Hsieh CH,Wu MH. Recent progress in enhanced cancer diagnosis, prognosis, and monitoring using a combined analysis of the number of circulating tumor cells (CTCs) and other clinical parameters. Cancers (Basel). 2023;15(22):5372.
378. 378..
     Wang PP,Liu SH,Chen CT,Lv L,Li D,Liu QY, et al. Circulating tumor cells as a new predictive and prognostic factor in patients with small cell lung cancer. J Cancer. 2020;11(8):2113-22.
379. 379..
     Nik Nabil WN,Xi Z,Liu M,Li Y,Yao M,Liu T, et al. Advances in thera-peutic agents targeting quiescent cancer cells. Acta Materia Medica.2022;1(1):56-71.
380. 380..
     Wang Y,Wang L,Wei Y,Wei C,Yang H,Chen Q, et al. Advances in the molecular regulation mechanism of tumor dormancy and its therapeu-tic strategy. Discov Oncol. 2024;15(1):184.
381. 381..
     Corrales E,Levit-Zerdoun E,Metzger P,Mertes R,Lehmann A,Münch J, et al. PI3K/Akt signaling allows for MAPK/ERK pathway independency mediating dedifferentiation-driven treatment resistance in melanoma. Cell Commun Signal. 2022;20(1):187.
382. 382..
     Sistigu A,Musella M,Galassi C,Vitale I,De Maria R. Tuning cancer fate:tumor microenvironment’s role in cancer stem cell quiescence and reawakening. Front Immunol. 2020;11:2166.
383. 383..
     Liu B,Zhou H,Tan L,Siu KTH,Guan XY. Exploring treatment options in cancer: tumor treatment strategies. Signal Transduct Target Ther.2024;9(1):175.
384. 384..
     Rusan M,Li K,Li Y,Christensen CL,Abraham BJ,Kwiatkowski N, et al. Suppression of adaptive responses to targeted cancer therapy by transcriptional repression. Cancer Discov. 2018;8(1):59-73.
385. 385..
     Cha JH,Chan LC,Song MS,Hung MC. New approaches on cancer immunotherapy. Cold Spring Harb Perspect Med. 2020;10(8):a036863.
386. 386..
     Liu X,Shen H,Zhang L,Huang W,Zhang S,Zhang B. Immunotherapy for recurrent or metastatic nasopharyngeal carcinoma. NPJ Precis Oncol. 2024;8(1):101.
387. 387..
     Christie AJ,Powers-James C,Narayanan S,Chen M,Eddy C,Gomez T, et al. Multidisciplinary lifestyle modification program (IM-FIT) for cancer survivors: implementation of a reimbursable model in a cancer hospital. Support Care Cancer. 2021;29(12):7365-75.
388. 388..
     Ellis KR,Raji D,Olaniran M,Alick C,Nichols D,Allicock M. A systematic scoping review of post-treatment lifestyle interventions for adult can-cer survivors and family members. J Cancer Surviv. 2022;16(2):233-56.
389. 389..
     Yadav AS,Pandey PR,Butti R,Radharani NNV,Roy S,Bhalara SR, et al. The biology and therapeutic implications of tumor dormancy and reactivation. Front Oncol. 2018;8:72.
390. 390..
     Serra V,Scaltriti M,Prudkin L,Eichhorn PJ,Ibrahim YH,Chandarlapaty S, et al. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene.2011;30(22):2547-57.
391. 391..
     Zhu S,Zhang T,Zheng L,Liu H,Song W,Liu D, et al. Combination strate-gies to maximize the benefits of cancer immunotherapy. J Hematol Oncol. 2021;14(1):156.
392. 392..
     Barbari C,Fontaine T,Parajuli P,Lamichhane N,Jakubski S,Lamichhane P, et al. Immunotherapies and combination strategies for immuno-oncology. Int J Mol Sci. 2020;21(14):5009.
393. 393..
     Nayak A,Warrier NM,Kumar P. Cancer stem cells and the tumor microenvironment: targeting the critical crosstalk through nanocarrier systems. Stem Cell Rev Rep. 2022;18(7):2209-33.
394. 394..
     Yeh AC,Ramaswamy S. Mechanisms of cancer cell dormancy-another hallmark of cancer?. Cancer Res. 2015;75(23):5014-22.
395. 395..
     Recasens A,Munoz L. Targeting cancer cell dormancy. Trends Pharma-col Sci. 2019;40(2):128-41.
396. 396..
     Mukherjee A,Bravo-Cordero JJ. Regulation of dormancy during tumor dissemination: the role of the ECM. Cancer Metastasis Rev.2023;42(1):99-112.